AB3A Stock Overview
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Sarepta Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$110.15 |
| 52 Week High | US$145.60 |
| 52 Week Low | US$55.52 |
| Beta | 0.95 |
| 1 Month Change | -2.95% |
| 3 Month Change | 3.09% |
| 1 Year Change | -3.21% |
| 3 Year Change | 82.43% |
| 5 Year Change | 4.61% |
| Change since IPO | 1,132.10% |
Recent News & Updates
Recent updates
Shareholder Returns
| AB3A | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -5.8% | -4.9% | -1.5% |
| 1Y | -3.2% | -19.9% | 0.9% |
Return vs Industry: AB3A exceeded the German Biotechs industry which returned -19.4% over the past year.
Return vs Market: AB3A underperformed the German Market which returned -0.4% over the past year.
Price Volatility
| AB3A volatility | |
|---|---|
| AB3A Average Weekly Movement | 5.4% |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: AB3A has not had significant price volatility in the past 3 months.
Volatility Over Time: AB3A's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1980 | 1,314 | Doug Ingram | www.sarepta.com |
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program.
Sarepta Therapeutics, Inc. Fundamentals Summary
| AB3A fundamental statistics | |
|---|---|
| Market cap | €10.40b |
| Earnings (TTM) | -€503.55m |
| Revenue (TTM) | €1.17b |
8.8x
P/S Ratio-20.4x
P/E RatioIs AB3A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AB3A income statement (TTM) | |
|---|---|
| Revenue | US$1.24b |
| Cost of Revenue | US$1.03b |
| Gross Profit | US$215.61m |
| Other Expenses | US$751.58m |
| Earnings | -US$535.98m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.71 |
| Gross Margin | 17.34% |
| Net Profit Margin | -43.11% |
| Debt/Equity Ratio | 144.1% |
How did AB3A perform over the long term?
See historical performance and comparison